Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 d...

Full description

Bibliographic Details
Authors: Garcia-Delgado, Regina, de Miguel, Dunia, Bailen, Alicia, Ramon Gonzalez, Jose, Bargay Lleonart, Joan, Falantes, Jose F., Andreu, Rafael, Fernando, Ramosh, Tormo, Mar, Brunet, Salut, Figueredo, M. A., Casaño, Javier, Medina, Angeles, Badiella, Llorenc, Fernandez Jurado, Antonio, Sanz, Guillermo, Asociacion Andaluza de Hematologia
Format: article
Publication Date:2014
Country:España
Institution:Conselleria de Salut i Consum del Govern de les Illes Balears
Repository:Docusalut
Language:English
OAI Identifier:oai:docusalut.com:20.500.13003/17327
Online Access:https://hdl.handle.net/20.500.13003/17327
Access Level:Open access
Keyword:Antimetabolites, Antineoplastic
Myelodysplastic Syndromes
Female
Male
Middle Aged
Retrospective Studies
Humans
Azacitidine
Leukemia, Myeloid, Acute
Adult
Aged, 80 and over
Aged
Proportional Hazards Models
Estudios Retrospectivos
Adulto
Modelos de Riesgos Proporcionales
Síndromes Mielodisplásicos
Femenino
Masculino
Humanos
Leucemia Mieloide Aguda
Azacitidina
Persona de Mediana Edad
Anciano de 80 o más Años
Anciano
Antimetabolitos Antineoplásicos
Acute myeloid leukemia
Dosing schedules
Myelodysplastic syndromes
Overall survival
Safety
Description
Summary:We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules.

Similar Items